Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Marker Study of Ipilimumab in Unresectable Stage III/IV Melanoma
2005-002126-64Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Correlation of pretreatment characteristics with clinical tumor response and Best overall response rate (BORR). Started Mar 2006; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-002126-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002126-64.